Product Description
Artesunate 20mg + Pyronaridine 60mg Granules: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
This page collects the supply-relevant facts for Artesunate 20mg + Pyronaridine 60mg Granules — specification, testing, packaging and the registration paperwork that travels with the batch.
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- One combination to handle with care MSF notes that the artesunate + sulfadoxine/pyrimethamine combination is contraindicated in HIV-infected women taking co-trimoxazole preventive therapy, and that artesunate/mefloquine should not be used where neurological signs developed during the acute phase. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
We quote these sources rather than paraphrase them loosely, because the detail matters commercially for Artesunate 20mg + Pyronaridine 60mg Granules. Where your national list differs from the WHO listing, the national list governs what may be supplied and promoted locally.
Artesunate 20mg + Pyronaridine 60mg Granules: Specification, Pack & Documentation Summary
| Product Name | Artesunate + Pyronaridine Granules (Artesunate 20mg + Pyronaridine 60mg Oral Granules) |
| Specification | Each sachet of granules contains: Artesunate 20mg + Pyronaridine 60mg (as Pyronaridine Phosphate) |
| Dosage Form | Oral Granules (for oral administration; dissolve in water before use) |
| Active Ingredients | Artesunate / Pyronaridine (as Pyronaridine Phosphate) |
| Pharmacological Class | Artemisinin Derivative + Mannich Base Antimalarial Combination (Artemisinin-based Combination Therapy, ACT) |
| Route of Administration | Oral administration. Dissolve the contents of one sachet in a small amount of clean drinking water and stir well before drinking. May be taken with or without food. |
| Storage | Store below 25°C, in a dry place, protected from light and moisture. Keep sachets sealed until use. Do not freeze. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Artesunate Suppositories 100mg, Artemether 80mg Injection, Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg, Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg, Artesunate 200mg + Amodiaquine 600mg Tablets, Artesunate 400mg Mefloquine 500mg Tablets.
How Artesunate 20mg + Pyronaridine 60mg Granules Is Tested and Released
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Every batch of Artesunate 20mg + Pyronaridine 60mg Granules is tested to the monograph stated on the purchase order. Where a monograph is silent on the presentation, we agree a written specification with you in advance and reference it on the certificate of analysis.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
Release testing on this presentation is built around:
- Testing for related substances and impurities
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
How Artesunate 20mg + Pyronaridine 60mg Granules Is Packed, Labelled and Shipped
- Pack size: Aluminum-plastic sachets, typically 12 sachets per box (blister or carton pack). Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, in a dry place, protected from light and moisture. Keep sachets sealed until use. Do not freeze..
- Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
- Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.
Regulatory Support for Artesunate 20mg + Pyronaridine 60mg Granules
Documents for Artesunate 20mg + Pyronaridine 60mg Granules are issued by Sinophare Bio-technology Co., Ltd. — DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. Keeping one legal manufacturer across the COA, the GMP certificate and the registration file avoids assessment queries later.
- Method validation, stability protocol and the shelf-life justification for the marketed pack.
- Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
- Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
The context for Artesunate 20mg + Pyronaridine 60mg Granules is its place among ACT regimens named in the WHO Model List of Essential Medicines. Listing status informs how programmes specify a product; it is not a substitute for the import licence or marketing authorisation of the destination country.
Questions We Are Asked About Artesunate 20mg + Pyronaridine 60mg Granules
What pack size is available for Artesunate 20mg + Pyronaridine 60mg Granules?
This presentation is normally supplied as Aluminum-plastic sachets, typically 12 sachets per box (blister or carton pack). Where your market requires a different count, bottle or carton, we quote to your artwork and extend the stability file to the new pack.
What documentation comes with a shipment of Artesunate 20mg + Pyronaridine 60mg Granules?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months.
Does the batch documentation for Artesunate 20mg + Pyronaridine 60mg Granules support a registration filing?
Shipments are accompanied by a certificate of analysis covering identification, assay and related substances, together with the marketed-pack stability data and the manufacturing site GMP certificate. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Do you supply dispersible paediatric ACTs?
Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.
Can you support registration in my market?
We provide COA, HPLC and GC analytical data, stability data, DMF and dossier packages together with registration support documents. DML Number Jin20160068 covers our medicines production.
Companion Products — Malaria & ACTs
- Artesunate Suppositories 100mg — 100mg
- Artemether 80mg Injection — 80mg
- Chloroquine Phosphate 500mg Tablets — 500mg
- Dihydroartemisinin 40mg + Piperaquine 320mg Tablets — 40mg
- Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg — 175mg
- Sulfadoxine Pyrimethamine 175mg + Dihydroartemisinin 60mg — 175mg
Browse the full Malaria & ACTs range; all Malaria & ACTs; the complete product catalogue.
Request a Quotation for Artesunate 20mg + Pyronaridine 60mg Granules
For tenders and programme supply, send the line item, pack size, quantity and destination for Artesunate 20mg + Pyronaridine 60mg Granules 20mg. We return a quotation with lead time, documentation list and sample availability in one response.
Sources & Regulatory Notes
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
